Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 5:50 AM ET


Company Overview of Chimerix, Inc.

Company Overview

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds include brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, as well as to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections. Its preclinical testing product includes CMX669 for the treatment of BK virus and CMV. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of ...

2505 Meridian Parkway

Suite 340

Durham, NC 27713

United States

Founded in 2000

123 Employees





Key Executives for Chimerix, Inc.

Chief Executive Officer, President, Chief Medical Officer and Director
Age: 48
Total Annual Compensation: $419.3K
Chief Commercial Officer
Age: 51
Total Annual Compensation: $333.6K
Chief Medical Officer
Age: 46
Total Annual Compensation: $128.5K
Chief Development Officer
Age: 61
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2014.

Chimerix, Inc. Key Developments

Chimerix, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 11:45 AM

Chimerix, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 11:45 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: M. Michelle Berrey, Chief Executive Officer, President, Chief Medical Officer and Director, William Garrett Nichols, Chief Medical Officer.

Chimerix Mulls Acquisitions

Chimerix, Inc. (NasdaqGM:CMRX) has filed a shelf registration to issue securities. Chimerix intends to use the net proceeds from the sale of the securities for general corporate purposes, which may include clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement its business.

Chimerix, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Chimerix, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported net loss of $32.4 million, or $0.70 per basic and diluted share, for the third quarter of 2015. During the same period in 2014, the company recorded a net loss of $17.0 million, or $0.47 per basic and diluted share. Revenues for the third quarter of 2015 increased to $2.3 million compared to $1.2 million for the same period in 2014, due to an increase in the third quarter of 2015 in reimbursable expenses associated with the company's ongoing development contract with BARDA. Loss from operations was $32.7 million for the third quarter of 2015, compared to a loss from operations of $16.9 million for the same period in 2014. The variance was primarily due to the increased research and development, and general and administrative expenses. For the nine months, the company reported total revenues of $7.652 million against $2.884 million a year ago. Loss from operations was $80.027 million against $38.640 million a year ago. Net loss was $79.529 million or $1.84 per basic and diluted share against $39.065 million or $1.26 per basic and diluted share a year ago.

Similar Private Companies By Industry

Company Name Region
Eleos, Inc. United States
Transcription Factor Therapeutics, Inc. United States
CDI Bioscience, Inc. United States
Histogen, Inc. United States
Kirax Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Chimerix, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at